2018
DOI: 10.15252/embj.2018100440
|View full text |Cite
|
Sign up to set email alerts
|

Excessive tubulin polyglutamylation causes neurodegeneration and perturbs neuronal transport

Abstract: Posttranslational modifications of tubulin are emerging regulators of microtubule functions. We have shown earlier that upregulated polyglutamylation is linked to rapid degeneration of Purkinje cells in mice with a mutation in the deglutamylating enzyme CCP1. How polyglutamylation leads to degeneration, whether it affects multiple neuron types, or which physiological processes it regulates in healthy neurons has remained unknown. Here, we demonstrate that excessive polyglutamylation induces neurodegeneration i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

13
179
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
4
2
1

Relationship

6
1

Authors

Journals

citations
Cited by 122 publications
(195 citation statements)
references
References 85 publications
13
179
0
Order By: Relevance
“…While the CCP1-associated human disease reported here represents a rare monogenic condition, dysregulation of tubulin polyglutamylation could also be involved in other neurodegenerative disorders. In a manuscript appearing in the same issue of this journal, Magiera and colleagues recognized neurodegeneration as a general response to impaired tubulin deglutamylation in mice with global ablation of neuronal deglutamylases activity (Magiera et al, 2018). In their manuscript, Magiera et al pinpointed a potential disease mechanism in tubulin deglutamylase-deficient neurons: They observed disturbed axonal transport, A Absent (A1, B1) or low-level CCP1 (D1) in patient-derived skin fibroblasts.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…While the CCP1-associated human disease reported here represents a rare monogenic condition, dysregulation of tubulin polyglutamylation could also be involved in other neurodegenerative disorders. In a manuscript appearing in the same issue of this journal, Magiera and colleagues recognized neurodegeneration as a general response to impaired tubulin deglutamylation in mice with global ablation of neuronal deglutamylases activity (Magiera et al, 2018). In their manuscript, Magiera et al pinpointed a potential disease mechanism in tubulin deglutamylase-deficient neurons: They observed disturbed axonal transport, A Absent (A1, B1) or low-level CCP1 (D1) in patient-derived skin fibroblasts.…”
Section: Discussionmentioning
confidence: 99%
“…Finally, the discovery of CCP1 deficiency as a cause of human neurodegeneration also entails a promising perspective that these disorders could become therapeutically accessible. Notably, Purkinje cell degeneration in pcd mice can be halted by counterbalancing tubulin glutamylation by genetic approaches (Rogowski et al, 2010;Berezniuk et al, 2012;Magiera et al, 2018). Since PTMs and their modifying enzymes are accessible targets for drug development (Huq & Wei, 2007), agents specifically modulating levels of tubulin polyglutamylation will probably soon become available.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…A key regulatory process that governs microtubule interaction with its cognate proteins is the diversity of tubulin genes and post-translational modifications (PTMs) (Janke, 2014). Most of the PTMs are reversible and defects in these PTM enzymes leads to abnormal levels of microtubule modifications, manifested in different disease pathologies (Magiera et al, 2018a) causing neurodegeneration (Magiera et al, 2018b) and cardiomyopathies (Chen et al, 2018;Robison et al, 2016).…”
Section: Introductionmentioning
confidence: 99%